Elamipretide

Elamipretide is a synthetic mitochondria targeting tetrapeptide used in research on mitochondrial function and related disorders, including preclinical and clinical studies; the catalogue label denotes the research grade peptide.

Elamipretide is associated with mitochondrial research as a mitochondria targeting synthetic tetrapeptide. FDA granted accelerated approval to defined Forzinity product(s) for improving muscle strength in adults and children weighing at least 30 kg with Barth syndrome; this narrow decision relies on a surrogate endpoint and requires confirmatory evidence. Broader primary mitochondrial myopathy and heart failure programmes remain investigational, with key randomised studies not showing benefit on their primary endpoints. This does not establish authorisation or equivalence for a catalogue material.

Elamipretide: Batch documents are not yet linked on this site. As a mitochondria targeting synthetic tetrapeptide, required evidence includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity declaration; peptide content, counterion and residual solvent/water information; and assay or potency data relevant to intended research applications. No batch documentation is shown as available until the record for that specific item is linked and reviewed.

Elamipretide: Storage depends on the documented supplied presentation; as a mitochondria targeting synthetic tetrapeptide verify dry/lyophilised or solution form, counterion and concentration, solvent or buffer selection, pH sensitivity, container closure compatibility and oxidation or aggregation propensity that influence physicochemical stability. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.